Surgery with immunotherapy and chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have stage III or IV non-squamous non-small cell lung cancer that cannot be removed by surgery alone.
- You have not had any prior cancer treatment (like chemotherapy, radiation, or immunotherapy).
- Your cancer does not have an EGFR mutation or ALK rearrangement.
- You are in fairly good health, able to do your daily activities with little or no help (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
This trial tests a combination of chemotherapy and an immunotherapy drug called sintilimab to shrink unresectable stage IIIB-IIIC non-small cell lung cancer, making it possible to remove it with surgery. The goal is to see if this approach can help patients who aren't candidates for surgery now become candidates later.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.